The takeaway in 30 seconds: On June 30, 2026, the SEC opened a 60-day public comment period on ETFs that invest in innovative asset classes or use novel investment strategies. The agency is asking foundational questions about whether certain novel ETFs qualify as investment companies, how they should be regulated, and how their registration should work.For RIAs, the headline isn’t the comment period itself. It’s the signal: novel ETF products are proliferating faster than the regulatory framework around them, and the duties RIAs already carry, due diligence, suitability, and truthful marketing, are the safeguards that have to hold while the framework catches up. This is a prompt to confirm those duties are documented practices, not assumptions.
The ETF market has grown from $4 trillion in 2019 to over $12 trillion at the end of 2025 (SEC, June 30, 2026 release). A meaningful share of that growth has come from products that look nothing like the broad market index funds ETFs were once synonymous with. These funds are built around innovative asset classes and novel strategies that did not exist, or were not available in ETF form, even a few years ago.
The SEC’s June 30 request for comment is an acknowledgment that the regulatory framework wasn’t built with these products in mind. The agency is asking genuinely foundational questions: whether certain novel ETFs qualify as investment companies under existing law, how they should be regulated, and how the registration process should handle them going forward. That’s not a minor clarification. It’s the SEC signaling that the ground under a fast-growing category of products is less settled than the products’ availability might suggest.
For RIAs, that uncertainty lands in a specific place. When the regulatory framework around a product is still being worked out, the adviser’s own duties, to understand what they are recommending, confirm it is suitable, and describe it honestly, become the primary line of investor protection. Not a secondary one. The primary one.
Why This Matters for RIAs Specifically
RIAs are not the subject of the SEC’s request for comment. Fund sponsors, exchanges, and the registration process are. But RIAs are where these products meet actual clients, and that’s where three existing fiduciary duties get tested by novelty.
The pattern is worth naming directly: a product can be available for purchase before the regulatory framework around it is fully settled, and before an adviser’s standard due diligence process is equipped to evaluate it. The fund cleared its path to market. That does not mean the adviser recommending it has done the work to understand it. The duty to do that work rests with the adviser, regardless of how the product was approved.
That’s the gap novel ETFs create. Not that they’re inherently inappropriate. Many serve legitimate purposes for the right client. The gap is that the adviser’s existing processes were built around conventional products, and a novel product can pass through those processes without receiving the scrutiny its novelty actually requires.
Three duties are where this surfaces.
1. Due Diligence Built for Conventional Funds Misses Novel Risk
Most RIAs have a product due diligence process. It was almost certainly designed around conventional funds: expense ratios, track record, manager tenure, holdings transparency, and the established questions for established products.
A novel ETF can clear that process while leaving its actual risks unexamined. A fund using a complex derivatives strategy, an unusual underlying asset, or a structure that behaves differently than its name suggests requires questions the conventional checklist doesn’t ask: How does this product behave in stressed conditions? What is the actual underlying exposure, as opposed to the marketed exposure? Is the structure one the adviser fully understands well enough to explain to a client?
The exposure: recommending a product the firm didn’t fully evaluate, because the evaluation process wasn’t built to catch what made the product novel. Under a fiduciary standard, “we ran it through our standard due diligence” is not a defense if the standard due diligence was structurally incapable of surfacing the relevant risk.
2. Suitability Disclosures That Don’t Match the Product’s Actual Risk
Suitability is a per-client analysis: is this specific product appropriate for this specific client’s objectives, risk tolerance, and circumstances. Novel ETFs strain that analysis in two directions.
First, the product’s risk profile may be harder to characterize than a conventional fund’s, which makes the suitability determination harder to make and harder to document. Second, retail clients may be drawn to novel products precisely because they’re novel, without understanding the risk, which puts more weight on the adviser’s documented suitability rationale.
The exposure: a suitability file that says a novel product was appropriate for a client without a documented rationale that engages with what actually makes the product risky. If an examiner asks why a complex or innovative product was suitable for a particular retail client, the answer needs to be a documented analysis, not a general statement that the client’s risk tolerance was “moderate to high.”
3. Marketing That Leans on “Innovative” Without Substantiation
When a firm recommends or holds novel products, the language describing them tends to drift toward the language the products use to market themselves: “innovative,” “next-generation,” and “differentiated access.” Under the Marketing Rule, any claim a firm makes about its investment approach has to be substantiated and can’t be misleading.
Describing a novel ETF strategy in promotional terms the firm cannot fully support, or in a way that overstates the strategy’s track record or understates its risk, is exactly the kind of claim the Marketing Rule was built to catch. The newer and less-established the product, the thinner the substantiation behind any performance or benefit claim tends to be.
The exposure: marketing materials that describe a firm’s use of innovative products in terms that sound compelling but cannot be backed by retained substantiation, and that, like all marketing claims, need a documented review trail showing the claim was evaluated before it went out.
The Common Thread
Look at all three. None of them is a new obligation created by the SEC’s request for comment. Due diligence, suitability, and truthful marketing are duties RIAs already carry. What novel ETFs do is stress test those duties by putting products in front of processes that were not designed for them.
That’s the real implication of the SEC’s announcement for RIAs. The regulatory framework around these products is being reconsidered, which means the period ahead is one where the products exist, the rules are in flux, and the adviser’s own duties are carrying more of the protective weight than usual. A firm whose due diligence, suitability, and marketing processes were built for conventional products is carrying a gap it may not have measured.
Problem → Solution → Outcome
The problem. Novel ETF products are reaching clients faster than the regulatory framework, and faster than most RIAs’ due diligence, suitability, and marketing processes, were built to handle. The adviser’s existing duties are the primary safeguard during that gap, but the processes supporting those duties were designed around conventional products and may pass novel ones through without adequate scrutiny or documentation.
The shift. The firm treats novel products as a distinct category requiring an enhanced, documented evaluation, with a due diligence workflow that asks the questions novelty demands, a suitability rationale that engages with the product’s actual risk, and a marketing review that substantiates any “innovative” claim before it is published. Critically, each of these produces a retained record at the moment it happens.
The outcome. When an examiner asks how the firm evaluated a novel product, confirmed its suitability for a specific client, or substantiated a marketing claim about it, the answer is a documented workflow with a timestamped trail, not a reconstruction or an assurance. The firm can demonstrate it met its heightened duties during exactly the period when those duties mattered most.
This is the kind of workflow Smartria is built to support: structured due diligence and policy attestation processes that capture the evaluation as it happens, suitability and marketing review documentation tied to the specific product and client, and a retained audit trail across all of it, so the heightened scrutiny novel products require is documented by design rather than reconstructed under exam pressure.
What to Do With This
You don’t need to wait for the SEC to finalize anything. The duties already apply. This week:
- Pull your product due diligence process and ask whether it’s built for novelty. Does it ask how a product behaves under stress, what the actual underlying exposure is, and whether the firm understands the structure well enough to explain it? If it only covers conventional metrics, novel products are passing through under-examined.
- Review the suitability documentation for any novel or complex product currently held in client accounts. Does the file engage with what actually makes the product risky, or does it rely on a generic risk-tolerance statement? If it’s the latter, that’s the gap to close.
- Audit any marketing language describing innovative or differentiated strategies. For each claim, confirm there’s retained substantiation and a documented review. “Innovative” is a marketing claim like any other, and it needs to be supportable.
- Consider whether to comment. The SEC explicitly wants input on how to balance innovation with investor protection. An RIA with a perspective on how novel products affect advisory practice has a 60-day window to put it on the record.
If your processes already treat novel products as a distinct category with enhanced, documented scrutiny, this announcement changes nothing for you except confirming you were ahead of it. If they don’t, if novel products run through processes built for conventional ones, this is a well-timed, low-stakes prompt to close the gap before it becomes an exam finding.
